| 2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390. |
 |
| 2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis |
Annals of Oncology. 2023 Nov;34(Suppl. 4):S1536-S1537. |
|
| 2023-10 |
Risk of type 2 diabetes mellitus and hyperlipidemia in patients with chronic myeloid leukemia initiating tyrosine kinase inhibitors: A nationwide cohort study |
Pharmacoepidemiology and Drug Safety. 2023 Oct;32(Suppl. S1):575. |
|
| 2023-06 |
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors |
Journal of Clinical Oncology. 2023 Jun;41(16, Suppl.):Meeting Abstract 3148. |
|
| 2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462-S1463. |
|
| 2022-10 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression |
Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412. |
|
| 2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) |
Annals of Oncology. 2022 Sep;33(7):S565-S566. |
|
| 2022-07 |
Toward collaboration among cancer trials groups in Asia: TCOG perspective |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S449. |
|
| 2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S535. |
|
| 2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S478. |
|
| 2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S484. |
|
| 2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements |
Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009. |
|
| 2022-06 |
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma |
Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120. |
|
| 2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 |
Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):378. |
|
| 2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma |
Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550. |
|
| 2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors |
Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660. |
|
| 2021-09 |
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC) |
Annals of Oncology. 2021 Sep;32(Suppl. 5):S1074. |
|
| 2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2021 Sep;32(Suppl. 5):S377. |
|
| 2021-09 |
Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements |
Oncology Research and Treatment. 2021 Sep;44(Suppl. 2):222. |
|
| 2021-07 |
Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements |
Cancer Research. 2021 Jul;81(13, Suppl.):Abstract number CT010. |
|
| 2021-05 |
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 4090. |
|
| 2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):4143. |
|
| 2021-05 |
A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy |
Journal of Clinical Oncology. 2021 May;39(15, Suppl.):Abstract number 6025. |
|
| 2020-09 |
Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer |
Annals of Oncology. 2020 Sep;31(Suppl. 4):S268-S269. |
|
| 2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study |
Annals of Oncology. 2020 Sep;31(Suppl. 4):S1192. |
|
| 2020-05 |
Establishing the common oncology data model for the national biobank consortium of Taiwan |
Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Meeting Abstract e19283. |
|
| 2020-05 |
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435) |
Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Abstract number TPS4669. |
|
| 2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study |
Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 477. |
|
| 2020-02 |
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data |
Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 383. |
|
| 2019-10 |
Chemo-radiotherapy in adjuvant therapy of curatively resected pancreatic cancer: Lesions from TCOG T3207 study |
Annals of Oncology. 2019 Oct;30(Suppl. 6):75. |
|
| 2019-10 |
Interpretation the results of adjuvant chemotherapy in curatively resected pancreatic cancer |
Annals of Oncology. 2019 Oct;30(Suppl. 6):vi 78. |
|
| 2019-10 |
Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II |
Annals of Oncology. 2019 Oct;30(Suppl. 6):137. |
|
| 2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 |
Annals of Oncology. 2019 Oct;30(Suppl. 5):319. |
|
| 2019-02 |
A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC) |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 319. |
|
| 2019-02 |
Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2 |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 8. |
|
| 2019-02 |
A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number TPS468. |
|
| 2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma |
Journal of Clinical Oncology. 2019 Feb;37(4, Suppl.):Abstract number 269. |
|
| 2018-12 |
FOXO3a-driven alternation of metabolism dictates the gemcitabine sensitivity |
Cancer Science. 2018 Dec;109(Suppl. 2):871. |
|
| 2018-12 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation |
Cancer Science. 2018 Dec;109(Suppl. 2):866. |
|
| 2018-12 |
The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan |
Cancer Science. 2018 Dec;109(Suppl. 2):1437. |
|
| 2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P. |
|
| 2018-11 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype |
Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O. |
|
| 2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Annals of Oncology. 2018 Nov;29(Suppl. 9):50. |
|
| 2018-10 |
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P. |
|
| 2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P. |
|
| 2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1 |
Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251. |
|
| 2018-10 |
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P. |
|
| 2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P. |
|
| 2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study |
Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD. |
|
| 2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286. |
|
